Hedge funds last week sold more U.S. healthcare stocks than they bought for the first time in 14 weeks, Goldman Sachs said in ...

Bruker faced a tough 2024, with aggressive M&A, $600M preferred issuance, rising debt, and execution issues prompting a ...

In recent days, AbCellera and Bruker resolved their global patent dispute, with Bruker agreeing to pay US$36 million upfront plus ongoing royalties on Beacon Optofluidic platform sales. At the same ...

Investors may be wondering whether Bruker is quietly turning into a value opportunity, or if the recent noise is just a distraction from deeper issues in the business. The stock has bounced 6.8% over ...

Shares of scientific instrument company Bruker (NASDAQ:BRKR). jumped 4.7% in the morning session after a company it ...

Detailed price information for Abcellera Biologics Inc (ABCL-Q) from The Globe and Mail including charting and trades.

RI Research Instruments, a company that is majority-owned by Bruker Corporation (Nasdaq: BRKR), today announced orders for key components and enabling subsystems for the research gamma ray source of ...

Shareholders of Bruker Corp (Symbol: BRKR) looking to boost their income beyond the stock's 0.4% annualized dividend yield can sell the December 2026 covered call at the $60 strike and collect the ...

AbCellera has reached a settlement and patent-license agreement to resolve patent litigation with Bruker Corporation. The biotechnology company said Thursday that it will receive a $36 million payment ...

Discover how AI, flow chemistry, and NMR come together in the PiPAC project to revolutionize scalable and autonomous API ...